CII

VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD

Hollywood, FL July 1, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated...

NUCYNTA(TM) (tapentadol) CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain

New Centrally Acting Prescription Medicine Treats Pain in Two Ways RARITAN, N.J., June 23 /PRNewswire/ -- Patients suffering from acute pain and healthcare professionals who treat pain have a new treatment option: NUCYNTA(TM) (tapentadol) CII immediate release tablets. This new medication for...

GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder

RESEARCH TRIANGLE PARK, N.C., March 31 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK ) has entered into a co-promotion agreement with Shire plc (LSE: SHP, Nasdaq: SHPGY ) for Vy v a n s e(R) , to help improve the recognition and treatment of adult Attention Deficit Hyperactivi...

PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches

Other Strength Patches (12.5, 25, 75 and 100 mcg/hr) Not Affected RARITAN, N.J., Dec. 31 /PRNewswire/ -- PriCara(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., said today that one lot of 50 microgram/hour (mcg/hr) DURAGESIC(R) (fentanyl transdermal system) CII patches sold by Pr...

PriCara(TM) Recalls 25 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches

Other Strength Patches (12.5, 50, 75 and 100 mcg/hr) Not Affected RARITAN, N.J., Feb. 12 /PRNewswire/ -- PriCara(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. said today that all lots of 25 microgram/hour (mcg/hr) DURAGESIC(R) (fentanyl transdermal system) CII patches sold by...

Food Industry in India to Grow to $310 Billion by 2015: CII

New Delhi: The Indian food industry is estimated to be worth over $200 million and is expected to grow to $310 billion by //2015, said the Confederation of Indian Industry (CII). The growth of the food industry is also going to give a major thrust to the already booming food retail industry, wh...

Expanding Price Control Detrimental for Pharma Companies: CII

Expressing concern over the proposal to expand price control from 74 to 354 drugs in the proposed national pharmaceutical policy//, industry chamber CII today said the step will prove detrimental to the growth of the industry as well as the economy. "Healthy competition between pharma compani...

Watson Announces Limited Recall Of Fentanyl Transdermal System

..., FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch Web site at www.fda.gov/medwatch . Watson's Fentanyl Transdermal System cii is indicated for the management of persistent, moderate to severe chronic pain that requires continuous, around the clock opioid administration for an...

Roxane Laboratories, Inc. Announces the Launch of Risperidone Oral Solution 1mg/mL

...cal products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled- release tablets; nasal sprays, cytotoxics and cii narcotics. Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehring...

Roxane Laboratories, Inc. Announces the Launch of Levetiracetam Tablets and Oral Solution

...ical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and cii narcotics. Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehring...

CII in Medical Technology

New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)

PHILADELPHIA, May 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PP...

Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD

VYVANSE is the first oral ADHD stimulant medication with published data demonstrating symptom control at 13 hours post-dose in a pediatric clinical study CHICAGO, Oct. 29 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today anno...

Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg

...ical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled release tablets; nasal sprays, cytotoxics and cii narcotics. Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer In...

CII in Biological News

Scientists decoding genomic sequences of H1N1 using isolates from outbreak in Argentina

...sights into virus evolution. The Mailman School of Public Health researchers, led by Gustavo Palacios, PhD, assistant professor of Epidemiology and cii Director W. Ian Lipkin, MD, John Snow Professor of Epidemiology, and professor of Neurology and Pathology at Columbia University, plan to completely s...

Study reveals how viruses collectively decide the fate of a bacterial cell

...acked the dynamics of three key genes cro, cI and cii and their protein production. The decision circui...e a given cell. The researchers found that the cii gene acted as the gate for the system. Increasing the number of viruses drove the dynamic level of cii proteins past a critical point facilitating produc...

CII in Biological Technology

Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration

PHILADELPHIA, July 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-dai...

Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment

VYVANSE is the first stimulant to establish duration of efficacy from two hours up to 14 hours after administration in adults with ADHD HOLLYWOOD, Fla., July 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced res...

FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD

ADHD symptom control demonstrated from the first time point measured (1.5 hours) through 13 hours postdose PHILADELPHIA, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced that the US Food and Drug Adminis...

Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD

PHILADELPHIA, March 31 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, today announced a co-promotion agreement with GlaxoSmithKline plc (NYSE: GSK ) for VYVANSE(R) (lisdexamfetamine dimesylate) capsules CII with the aim of im...

Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies

... targeting certain tumor-associated proteins. The agreement with cii provides Morphotek access to several of CII's monoclonal antibodies. Morph...r the commercialization of the antibodies. "We are delighted that cii has decided to partner with Morphotek," said Nicholas C. Nicolaides, Ph.D.,...

Roxane Laboratories, Inc. Announces the Launch of Mycophenolate Mofetil 250mg Capsules and 500mg Tablets

...cal products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled- release tablets; nasal sprays, cytotoxics and cii narcotics. Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer...

Advanced Bionics Reaches Resolution With FDA, Settles Financial Suit

...cs' HiRes90K Implantable Cochlear Stimulator was based upon a recognition that the HiRes90K was a repackaging of the previous generation device called cii that used feedthrus from both vendors. Although the FDA did not accept these arguments, Advanced Bionics believes them to be true and denies that it...

A Positive Selection Assay for Mutation Analysis in Big Blue Animals

...s assay system that selects for mutations in the cii gene of coliphage lambda. The l Select-cII mut...ions to provide an environment where only lambda cii mutants form plaques. This assay not only pr...unctions as the mutational test sequence. 4 The cii gene encodes a protein that activates transcriptio...